- Home
- AEE vs WAT Comparison
AEE vs WAT Comparison
Compare AEE & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEE | WAT |
|---|---|---|
| Founded | 1901 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.2B | 29.2B |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | AEE | WAT |
|---|---|---|
| Price | $112.79 | $297.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | $113.10 | ★ $386.38 |
| AVG Volume (30 Days) | ★ 1.5M | 1.0M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | ★ 21.04 | 0.47 |
| EPS | 5.35 | ★ 10.76 |
| Revenue | ★ $8,799,000,000.00 | $3,165,286,000.00 |
| Revenue This Year | $7.32 | $104.66 |
| Revenue Next Year | $6.49 | $10.53 |
| P/E Ratio | ★ $21.14 | $27.40 |
| Revenue Growth | ★ 15.43 | 6.99 |
| 52 Week Low | $91.77 | $275.05 |
| 52 Week High | $113.93 | $414.15 |
Technical Indicators
Market Signals| Indicator | AEE | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 62.26 | 35.98 |
| Support Level | $109.52 | $281.33 |
| Resistance Level | $113.15 | $308.14 |
| Average True Range (ATR) | 1.70 | 8.60 |
| MACD | -0.22 | -0.05 |
| Stochastic Oscillator | 74.95 | 34.88 |
Price Performance
Historical ComparisonAbout AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and 800,000 natural gas customers across its two service territories.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.